Latest Lipitor Stories

- Arrow Will Expand Watson's Global Commercial Footprint - Transaction Expected to be Accretive to Cash Earnings Per Share in 2010 Before Synergies - Enhances Watson's Long Term Growth Profile MORRISTOWN, N.J., June 17 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in a global...

A new program announced on Thursday by the U.S. drug company Pfizer Inc. is allowing people who have lost their jobs and health insurance keep taking some widely prescribed Pfizer medications for free for up to a year, the Associated Press reported.The program even includes the popular cholesterol drug Lipitor and the sexual dysfunction aid Viagra.Pfizer will make more than 70 of its prescription drugs available at no cost to unemployed, uninsured Americans, who lost jobs since Jan. 1 and...

Pfizer has reported positive findings from a post hoc sub-analysis of the five-year Treating to New Targets study. According to the company, improvements in kidney function in patients treated with Lipitor were shown to strongly correlate with a reduced risk of major cardiovascular events in patients with pre-existing cardiovascular disease. In this new post hoc analysis, kidney function was assessed using estimated glomerular filtration rate (eGFR), as recommended by the National Kidney...

Improvements in kidney function in patients treated with Lipitor(R) (atorvastatin calcium) were shown to strongly correlate with a reduced risk of major cardiovascular events in patients with pre-existing cardiovascular disease, according to a post hoc sub-analysis of the five-year Treating to New Targets (TNT) study presented today at the Annual Scientific Sessions of the American Heart Association. "This is the first time for any statin that an association between improvements in kidney...

Aegerion Pharmaceuticals, a biopharmaceutical company engaged in the treatment of cardiovascular and metabolic disease, has announced positive top-line data from three separate Phase II trials involving its lead cholesterol management compound, AEGR-733, which is a microsomal triglyceride transfer protein inhibitor. All three trials were designed to evaluate the efficacy, safety and tolerability of low doses of AEGR-733 alone and in combination with other lipid lowering agents such as...

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced top-line data from three separate Phase II trials involving its lead cholesterol management compound, AEGR-733, which is a microsomal triglyceride transfer protein (MTP) inhibitor. All three trials were designed to evaluate the efficacy, safety and tolerability of low doses of AEGR-733 alone and in combination with other lipid lowering agents such as...

Lipitor has been the top-selling drug in the world and has accounted for over $12 billion in annual sales. It has been prescribed to both men and women to lower cholesterol and reduce the risk of heart attack and stroke in patients with common risk factors for heart disease. However, a new study appearing in the Journal of Empirical Legal Studies was unable to find high quality clinical evidence documenting reduced heart attack risk for women in a primary prevention context. Furthermore,...

Six months after Lipitor ads were yanked off TV amid complaints of misleading advertising, parent company Pfizer Inc. (PFE) has put the world's top-selling cholesterol fighter back in the spotlight. Last time around Pfizer used a celebrity doctor endorser who's never practiced medicine. But this time, Pfizer is leaving out the celebrity.In the new television ads, the spokesman is a talent agent from the San Francisco Bay area who tells viewers he started taking Pfizer's Lipitor after...

Pfizer announced that in patients with established heart disease, Lipitor(R) (atorvastatin calcium) 80 mg not only significantly reduced the relative risk of suffering a first cardiovascular event by 19 percent compared to Lipitor 10 mg but also provided a sustained reduction in the risk of a subsequent second, third, fourth, and fifth cardiovascular event, according to a subanalysis of the five-year Treating to New Targets (TNT) study. This subanalysis, designed and completed following...

By Anonymous DR. ROBERT JARVIK doesn't row. The spokesperson for Pfizer's cholesterol-lowering medication Lipitor also isn't a cardiologist, nor is he licensed to practice medicine. And former colleagues even contest his claim to be the "inventor of the Jarvik artificial heart." After a Congressional committee began looking into the misrepresentation of Jarvik's credentials, Pfizer pulled long- running Lipitor commercials featuring Jarvik off the air in February. Pfizer spent more than $258...